• Dyadic International reported the Japan Patent Office allowed claims covering its Thermothelomyces heterothallica recombinant protein expression technology.
• Decision extends IP protection for the company’s C1 and Dapibus microbial protein production platforms in Japan.
• Dyadic engaged Intralink to support business development in Japan, with partner meetings scheduled for early July.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dyadic International Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606290725PRIMZONEFULLFEED9753869) on June 29, 2026, and is solely responsible for the information contained therein.